Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 6/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | MCOLN2 | Q8IZK6 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5149109 | 0.92 | HRH4 (0.43) | NPSR1ADORA2AADORA1MAPTCHEK1 | |
| SCHEMBL5152699 | 0.92 | MAPT (0.40) | HRH3NPSR1ADORA2AADORA1MAPT | |
| SCHEMBL5149198 | 0.92 | SIRT1 (0.43) | HRH3NPSR1ADORA2AADORA1MAPT | |
| SCHEMBL5150685 | 0.91 | HSD17B10 (0.42) | NPSR1ADORA2AADORA1MAPTMEN1 | |
| SCHEMBL5149031 | 0.91 | ALDH1A1 (0.41) | HRH3NPSR1ADORA2AADORA1MAPT | |
| SCHEMBL5150733 | 0.89 | ATR (0.37) | ADORA2AADORA1USP2ALOX15HSD17B10 | |
| SCHEMBL5152349 | 0.88 | SMO (0.46) | NPSR1ADORA2AADORA1MAPTABCG2 | |
| SCHEMBL5149290 | 0.88 | LMNA (0.43) | NPSR1MAPTDHFRMEN1KMT2A | |
| SCHEMBL5149038 | 0.86 | HRH3 (0.46) | HRH3NPSR1ADORA2AADORA1MAPT | |
| SCHEMBL5147939 | 0.85 | HRH3 (0.39) | HRH3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265120-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2007-09-04 | — | — | US | disclosed |
| CN-1938296-A | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists | ASTELLAS PHARMA INC (JP) | 2007-03-28 | — | — | CN | disclosed |
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222159-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, HTR5A, ADORA1 | HRH3 43/4885NPSR1 116/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.